Glucagon-like peptide 1 receptor agonists improve glucose control, promote weight loss and reduce the risk of major cardiovascular events in people with type 2 diabetes mellitus. The FLOW study now provides unequivocal evidence of kidney protective effects with semaglutide in adults with type 2 diabetes mellitus and chronic kidney disease.

中文翻译：

---

GLP-1受体激动剂革命降临肾脏病学


胰高血糖素样肽 1 受体激动剂可改善 2 型糖尿病患者的血糖控制、促进体重减轻并降低主要心血管事件的风险。 FLOW 研究现在提供了索马鲁肽对 2 型糖尿病和慢性肾病成人患者的肾脏保护作用的明确证据。